<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52040">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02022930</url>
  </required_header>
  <id_info>
    <org_study_id>COR1.1</org_study_id>
    <nct_id>NCT02022930</nct_id>
  </id_info>
  <brief_title>Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Hydros and Hydros-TA Joint Therapies for Management of Pain Associated With Osteoarthritis in the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carbylan BioSurgery, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carbylan BioSurgery, Inc.</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Hydros-TA Joint Therapy
      for relief of pain due to OA of the knee.  Hydros-TA is designed to provide fast acting and
      long lasting pain relief for up to six months with a single IA injection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in the WOMAC A subscale score for the treatment knee.</measure>
    <time_frame>2 weeks and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Strict positive responders to treatment for symptomatic primary osteoarthritis of the knee</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Hydros</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydros Joint Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydros-TA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydros-TA Joint Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone acetonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Triamcinolone acetonide</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydros</intervention_name>
    <arm_group_label>Hydros</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydros-TA</intervention_name>
    <arm_group_label>Hydros-TA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <arm_group_label>Triamcinolone acetonide</arm_group_label>
    <other_name>Triamcinolone Acetonide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have radiographic evidence within the prior 6 months, as shown in the radiology
             reports, of OA grade 2 or 3 using Kellgren-Lawrence Grading for OA.

          -  Symptoms in the index knee for at least 12 months.

          -  Fully ambulatory Subject (ability to perform a 15 meters walk test).

          -  Male and female Subjects 40 through 85 years of age.

        Exclusion Criteria:

          -  BMI &gt;40 kg

          -  Secondary OA (acute knee injury, rheumatoid arthritis, gout, history of joint
             infection, osteonecrosis, chronic fibromyalgia) or other chronic autoimmune disease.

          -  Intra articular steroid therapy in last 3 months

          -  Intra articular viscosupplementation in last 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marcee Maroney</last_name>
    <phone>650 8556774</phone>
    <email>mmaroney@carbylan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>St.Leonards</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Oshawa</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Willemstad</city>
        <state>Curacao</state>
        <country>Netherlands Antilles</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Netherlands Antilles</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 25, 2014</lastchanged_date>
  <firstreceived_date>December 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
